Access to the pharmaceutical market: strategy, science and purpose

No episode 110 from AmplificaCast, Eric Klein receives Rafael CostaCommercial Director, Market Access, Marketing and Strategic Alliances at BIOMMfor an in-depth conversation about access to the pharmaceutical market ...and the strategic behind-the-scenes decisions in a highly regulated sector. Far beyond traditional sales or marketing, the episode reveals how science, public policy, ethics, and communication connect to ensure that medicines reach those who truly need them.

For marketing, sales, and business leaders, the content provides applicable insights into positioning in complex environments, building reputation, and generating value across multiple decision-making chains.

Access to the pharmaceutical market begins before the sale.

A common mistake when talking about access to pharmaceutical market It's not about reducing the concept to negotiation with the government or the inclusion of a product in the SUS (Brazilian public healthcare system). The conversation makes it clear that access begins long before that.

It begins with a deep understanding of the patient journey, moves through the generation of robust scientific evidence, involves relationships with strategic stakeholders, and only then translates into commercial execution.

Rafael explains that the regulatory environment is not an obstacle to be overcome, but a structure that organizes the game. There is regulation from Anvisa (Brazilian Health Regulatory Agency), there are guidelines from the Ministry of Health, there are medical protocols, and there are cost-effectiveness criteria. Ignoring any of these layers compromises access to the pharmaceutical market in a structural way.

The key difference lies in knowing how to connect these interests into a coherent and sustainable narrative.

Evidence-based communication as a strategic pillar

If there's one central point in this conversation, it's the importance of science-backed communication. In accessing the pharmaceutical market, there's no room for empty rhetoric.

The doctor needs consistent clinical data.
The government demands economic sustainability.
The patient wants safety and quality of life.
The system needs predictable supply.

This means that communication, in this context, is not advertising, but structured education.

Rafael emphasizes that translating science into value is an essential skill. It's not just about explaining the mechanism of action, but about demonstrating the real impact on the patient's journey and the healthcare system as a whole.

For B2B marketing decision-makers, this is a powerful insight: the more complex the market, the more strategic the communication must be.

Public policies as a driver of access to the pharmaceutical market.

One of the most relevant parts of the episode is when Rafael details the PDP and technology transfer projects. Here, access to the pharmaceutical market takes on a macroeconomic dimension.

It's not just about selling a drug. It's about strengthening the national manufacturing base, reducing import dependence, ensuring continuous supply, and generating local knowledge in biotechnology.

In explaining the national production of insulin glargine and the partnerships with public institutions, he shows that Access involves a long-term strategy.These are projects that last for years and require coordination between the private sector, government, and regulatory bodies.

For business leaders, the lesson is clear: complex markets demand a systemic vision. Sustainable growth rarely happens through isolated actions. It arises from well-constructed ecosystems.

Leadership in regulated environments requires maturity.

Another important point of the conversation is leadership development. Rafael began his career at the counter, moved into sales, and built his career path to director. This movement reveals something essential for anyone who wants to work in this field. aAccess to the pharmaceutical market: technical knowledge is important, but Relationship skills are crucial..

He highlights three pillars that underpin professional reputation: trust, transparency, and consistency.

Without trust, there is no sustainable negotiation.
Without transparency, there is no credibility.
Without consistency, there is no longevity.

In regulated markets, Reputation is a strategic asset.Reputation is built on details, on the consistency between words and actions.

For executives who lead sales or marketing teams, this reinforces the importance of developing soft skills, active listening, and the ability to coordinate across departments.

Education as a long-term strategy

When discussing diabetes, awareness, and patient support programs, the episode reinforces that access to the pharmaceutical market also depends on education.

Accurate information impacts adherence to treatment.
Adherence impacts clinical outcome.
Clinical outcomes impact the sustainability of the system.

It's a cycle.

When industry invests in education and structured programs, it's not just communicating its brand. It's strengthening the very ecosystem that enables access.

This reasoning can be applied to other sectors. Companies that educate the market reduce commercial friction, increase customer maturity, and accelerate strategic decisions.

Education is about positioning, differentiation, and building authority.

The role of purpose in accessing the pharmaceutical market.

A key moment in the conversation occurs when Rafael shares personal experiences with diabetes in his family. This point humanizes the discussion and reinforces that access to the pharmaceutical market is not just a corporate strategy, but a real impact on people's lives.

But he also makes it clear that purpose does not replace process.

Passion is important, but method is essential.
And ethics? That's non-negotiable.

This combination is what underpins complex decisions and long-term negotiations.

For leaders, the lesson is straightforward: companies that want to operate in critical sectors need to align purpose with governance. This argument only holds up when... the execution follows.

What decision-makers can apply to their own business.

Even if your company is not in the pharmaceutical industry, the concept of access to the pharmaceutical market offers valuable lessons.

First: deeply understand the decision-making chain of your market.
Second: build a narrative based on data, not just promises.
Third: align stakeholders before communicating externally.
Fourth: treat reputation as a strategic asset.

Complex markets do not tolerate improvisation.
They require planning, consistency, and a long-term vision.

Executives who understand this build more resilient brands and more sustainable businesses.

Access to the pharmaceutical market as a competitive advantage.

As the healthcare sector evolves, with new technologies such as GLP-1, biosimilars, and advanced biotechnology, access to the pharmaceutical market becomes even more strategic.

Developing innovation is not enough; access must also be made possible.
Having the technology isn't enough; it needs to be connected to public policies, regulation, and sustainability.

Companies that master this integration gain a competitive advantage.

Strategic communication, sound science, and a systemic vision are the pillars that support growth in regulated markets.

Do you want to deepen your understanding of access to the pharmaceutical market?

Watch the episode 110 from AmplificaCast with Rafael Costa And understand, in practice, how access to the pharmaceutical market works in one of the most strategic sectors of the economy. If you are a marketing, sales, or executive leadership decision-maker and seek to broaden your understanding of strategy, regulation, and positioning, this episode is essential.